指南与共识痛风与晶体性关节病

2020年美国风湿病学会痛风管理指南

2020 American College of Rheumatology Guideline for the Management of Gout.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2020-05-11

采用GRADE方法系统评价证据并经共识流程形成推荐。

要点

  • 痛风石、影像学损伤或频繁发作者强推荐启动ULT,别嘌醇为一线首选。
  • 别嘌醇起始剂量≤100 mg/日(CKD更低),非布司他<40 mg/日,采用达标治疗策略,SU目标<6 mg/dl。
  • 启动ULT时强推荐至少3-6个月抗炎预防;急性发作强推荐秋水仙碱、NSAIDs或糖皮质激素。

核心结论

  • 该指南基于GRADE方法及共识流程,为痛风管理提供方向性推荐。

研究设计与样本

  • 制定机构为美国风湿病学会(ACR),采用GRADE方法系统评价证据并结合患者输入与共识流程形成推荐。

关键数值与推荐

  • 强推荐所有痛风石、痛风所致影像学损伤或频繁痛风发作的患者启动ULT。
  • 强推荐别嘌醇作为首选一线ULT,包括中重度慢性肾脏病(CKD;分期>3)患者。
  • 强推荐别嘌醇起始剂量≤100 mg/日(CKD患者更低)或非布司他<40 mg/日。
  • 强推荐达标治疗策略,依据系列血尿酸(SU)测量调整ULT剂量,SU目标<6 mg/dl。
  • 启动ULT时强推荐联用抗炎预防治疗至少3-6个月。

临床怎么用

  • 临床可根据患者痛风石、影像学损伤或发作频率决定是否启动ULT,并首选别嘌醇。
  • 起始ULT时采用低剂量并联合抗炎预防至少3-6个月,按SU目标<6 mg/dl调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide guidance for the management of gout, including indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations. METHODS: Fifty-seven population, intervention, comparator, and outcomes questions were developed, followed by a systematic literature review, including network meta-analyses with ratings of the available evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group consensus process was used to compose the final recommendations and grade their strength as strong or conditional. RESULTS: Forty-two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (<40 mg/day); and a treat-to-target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for a duration of at least 3-6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended. CONCLUSION: Using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions on the management of gout.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020. PMID: 32391934. doi:10.1002/acr.24180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。